European Review for Medical and Pharmacological Sciences. 2022 Jul
J. HUANG, Y. DING, J. YAO, K. PENG, K. DENG, M. ZHANG, Y. ZHANG, J. ZUO
Products used in the paper Details Operation
HEK-293T/ACE2
cells (CAT#nCov-3), and SARS-CoV-2_del19AAGFP
pseudovirus (CAT#LV-nCov2)
Freund’s incomplete adjuvant (CAT#B545288, Sangon Biotech, Shanghai, China), HEK-293T/ACE2 cells (CAT#nCov-3), and SARS-CoV- 2_del19AAGFP pseudovirus (CAT#LV-nCov2) were purchased from Packgene, Guangzhou, Guangdong, China. Request Quote

Research Field: Covid-related

Keywords: COVID-19, Enevolpe protein, Spike protein, Nanovaccine, PLGA

Abstract

OBJECTIVE: Vaccination is an important method for preventing COVID-19 infection. However, certain vaccines do not meet the current needs. To improve the vaccine effect, discard ineffective antigens, and focus on high-quality antigenic clusters, S1-E bivalent antigens were designed.

MATERIALS AND METHODS: Vaccine delivery is performed using poly (lactic-co-glycolic acid) (PLGA). Here, the recombinant S1-E (rS1-E) was covered on PLGA and injected intramuscularly into mice. In total, 48 BALB/c mice were randomly divided into six groups with 8 mice in each group. The mice received intramuscular injections. Prior to vaccination, the hydrophobicity of the rS1-E and the antigenic site of the E protein were both analysed. The morphology, zeta potential, and particle size distribution of rS1-E-PLGA were examined. Anti-S1 and anti-E antibodies were detected in mouse serum by ELISA. Neutralising an-tibodies were detected by co-incubating the pseudovirus with the obtained serum. IL-2 and TNF-α levels were also measured.

RESULTS: The designed recombinant S1-E protein was successfully coated on PLGA nanoparticles. rS1-E-PLGA nanovaccine has suitable size, shape, good stability, sustained release and other characteristics. Importantly, mice were stimulated with rS1-E-PLGA nanovaccines to produce high-titre antibodies and a good cellular immune response. CONCLUSIONS: Our results indicate that rS1-E-PLGA nanovaccine may provide a good protective effect, and the vaccine should be further investigated in human clinical trials for use in vaccination or as a booster.

Popular Services

AAV Packaging Service

AAV Analytical Service

Vector Design